Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced its ...
The NICD and NHLS were ordered by the High Court to release personal and medical information related to the Tiger Brands ...
Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseases Cue Biopharma plans to initiate global Phase 2b trial in food allergy followin ...
UCB acquires IMIDomics’ Patient Insight Business, gaining access to one of the world’s most comprehensive multi omic datasets for immune mediated inflammatory diseasesPatient Insight Business enhances ...
SC allowed classification of Odomos under HSN 38089191 to stand, holding that market identity and consumer understanding ...
Chronic viral infections, including HPV, HIV, viral hepatitis, and herpesviruses, affect over a billion people worldwide and are responsible for millions of ...
KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late ...
Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) securities between November 3, ...
The dismantling of public health through NIH funding cuts, CDC censorship and Medicaid rollbacks is a deliberate attack on ...
It’s a mobile app that provides real-time, hyperlocal risk information about disease-carrying insects and arachnids. The app ...
Chow is an alumnus of the Epidemic Intelligence Service program (2018-2020) and serves as the president-elect for the ...
The company has rallied from an earlier setback in obesity thanks to early progress for a drug targeting “NLRP3,” an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results